Clinical trials: Ophthalmology
Corneal Endothelial Cell Dysfunction, Corneal Endothelial Cell
Safety and Efficacy of Cultivated Allogeneic Corneal Endothelial Cells Attached to a Hydrogel Substrate (Endo-Tek™) as a Treatment for Corneal Endothelial Cell Dysfunction
Primary Objective: To determine the safety and feasibility of using Endo Tek™ for the treatment of corneal endothelial disease/dysfunction.
- Trial name
- NCT07874503
- Testing
- HCEC graft
- Where
- El Salvador
- Volunteers
- 30 people
- Sponsor
- OcuCell
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-1 (NCT04246801)
- Testing
- Clobetasol propionate, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 250 people
- Sponsor
- Salvat
Neovascular Age-related Macular Degeneration (nAMD)
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
- Trial name
- NOVA-1 (NCT05769153)
- Testing
- AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant
- Where
- 42 sites in United States
- Volunteers
- 139 people
- Sponsor
- Alcon Research
Myopia
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of moderate to high myopia (nearsightedness), when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
- Trial name
- NCT00762541
- Testing
- MEL 80 Treatment of High Myopia
- Where
- 5 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec, Inc.
Dry Eye, Dry Eye Syndromes
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
This is a multi-center, double-masked, randomized, vehicle-controlled study testing PL9643, an ophthalmic solution to determine if safe and efficacious for dry eye patients.
- Trial name
- MELODY-1 (NCT05201170)
- Testing
- Vehicle Ophthalmic Solution, PL9643 Ophthalmic Solution
- Where
- 18 sites in United States
- Volunteers
- 575 people
- Sponsor
- Palatin Technologies, Inc
Retinal Disease, Macular Degeneration
Stem Cell Ophthalmology Treatment Study
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease. http://mdstemcells.com/scots-ii/
- Conditions
- Retinal Disease, Macular Degeneration, Hereditary Retinal Dystrophy, Optic Nerve Disease
- Trial name
- SCOTS (NCT01920867)
- Testing
- RB (Retrobulbar), ST (Subtenon), IV (Intravenous)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- MD Stem Cells
Abdominal Pain/Gastrointestinal Issues, Lower Respiratory System Conditions
Clinic Waiting Room-based Study of Swahili Language Artificial Intelligence-driven Symptom Assessments in Tanzanian Primary Health Care Facilities
This study will evaluate the accuracy of the condition suggestions and urgency advice of the Swahili language Ada symptom assessment application (SAA), when symptoms are input by a lay-person user and a medical professional…
- Conditions
- Abdominal Pain/Gastrointestinal Issues, Lower Respiratory System Conditions, Upper Respiratory System Conditions, Mental Health Conditions
- Trial name
- AFYA (NCT04958577)
- Testing
- Ada Waiting Room App (WRA) and Ada Diagnostic Support Application (HDA)
- Where
- Tanzania
- Volunteers
- 109 people
- Sponsor
- Ada Health GmbH
Dry Eye Syndromes, Dry Eye
The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease
The central hypothesis is that inflammation contributes to dry eye and that rinsing the palpebral conjunctiva, bulbar conjunctiva, and fornices will reduce the inflammatory burden on the ocular surface.
- Conditions
- Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
- Trial name
- RINSE-A (NCT07618364)
- Testing
- Rinsada
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Rinsada
Age-related Macular Degeneration (AMD)
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
The purpose of this study is to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary care and ophthalmology settings.
- Trial name
- NCT07084883
- Testing
- No intervention.
- Where
- United States
- Volunteers
- 1,076 people, healthy volunteers welcome
- Sponsor
- iHealthScreen Inc
Postoperative Ocular Inflammation, Postoperative Ocular Pain
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
This study is designed to evaluate the safety and efficacy of TRIESENCE® (triamcinolone acetonide injectable suspension) in patients undergoing ophthalmic procedures.
- Trial name
- NCT07832552
- Testing
- TRIESENCE (triamcinolone acetonide injectable suspension)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Harrow Inc
Mixed Astigmatism
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of mixed astigmatism up to 6.0 D, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
- Trial name
- NCT00761826
- Testing
- MEL 80 Mixed Astigmatism Treatment
- Where
- 5 sites in United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec, Inc.
Allergic Conjunctivitis
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
- Trial name
- NCT00445874
- Testing
- Ketotifen with a Contact Lens (no generic name)
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vistakon Pharmaceuticals
Ophthalmology, Macular Degeneration
A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe
With this follow up physician survey researcher want to collect the same data from all participants of the study using a highly structured questionnaire.
- Trial name
- NCT04067583
- Testing
- Physician questionnaire
- Where
- Germany
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Bayer
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
- Trial name
- VOYAGER (NCT05476926)
- Testing
- Faricimab, Port Delivery System with Ranibizumab
- Where
- 299 sites in United States, Argentina and 27 more
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Dry Eye Syndromes
Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome
The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.
- Trial name
- NCT03821415
- Testing
- RP101
- Where
- 8 sites in Austria, Germany and 1 more
- Volunteers
- 104 people
- Sponsor
- Redwood Pharma AB
Healthy
Safety and Tolerability Study of Transscleral Iontophoresis by the EyeGate® II Drug Delivery Device System
The purpose of this study is to evaluate the safety and tolerability of a single iontophoretic dose of buffered solution administered through the EyeGate® II Drug Delivery System in healthy adult human volunteers.
- Trial name
- NCT00698425
- Testing
- EyeGate II® Drug Delivery System, Citrate buffer
- Where
- India
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Metastatic Uveal Melanoma, Cutaneous Melanoma
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including…
- Conditions
- Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
- Trial name
- NCT03947385
- Testing
- IDE196, Binimetinib, Crizotinib
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 336 people
- Sponsor
- IDEAYA Biosciences
Retinal Disease, Age-Related Macular Degeneration
Stem Cell Ophthalmology Treatment Study II
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease
- Trial name
- SCOTS2 (NCT03011541)
- Testing
- Arm 1
- Where
- 4 sites in United States, Austria and 1 more
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Geographic Atrophy, Age-Related Macular Degeneration
Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD).
- Trial name
- K8 for GA (NCT06164587)
- Testing
- K8
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- Inflammasome Therapeutics
Healthy Subjects
A Phase 1, Open-Label, 10 Day Safety Study
This is a Phase 1 open-label study in healthy volunteers who will receive oral 200 mg TR 701 FA once daily for 10 days and will include ophthalmologic and neurologic assessments.
- Trial name
- NCT01623401
- Testing
- TR-701 FA
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)